Day: January 29, 2025

FLORHAM PARK, N.J., Jan. 29, 2025 (GLOBE NEWSWIRE) — Phathom Pharmaceuticals, Inc. (Nasdaq: PHAT), a biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal (GI) diseases, announced today that members of the management team will participate in a fireside chat at the Guggenheim Securities SMID Cap Biotech Conference on Thursday, February 6, 2025, at 10:00 am ET. Company management will also participate in one-on-one meetings during the conference, which will run from February 5-6, 2025, in New York, NY. To access the live webcast and archived recording of the event, visit the Events & Presentations section of the Phathom website at https://investors.phathompharma.com/news-events/events-and-presentations. A recording will be available for 90 days following the conclusion of the...

RIDGEFIELD, Conn., Jan. 29, 2025 (GLOBE NEWSWIRE) — The Chefs’ Warehouse, Inc. (NASDAQ: CHEF) today announced that the Company intends to release its financial results for the fourth quarter and fiscal year ended December 27, 2024 before the opening of the stock market on Wednesday, February 12, 2025 and host a conference call at 8:30 a.m. ET on Wednesday, February 12, 2025 to review those results. The conference call will be webcast live from the Company’s investor relations website at http://investors.chefswarehouse.com/. An online archive of the webcast will be available on the Company’s investor relations website for 30 days. About The Chefs’ Warehouse The Chefs’ Warehouse, Inc. (http://www.chefswarehouse.com) is a premier distributor of specialty food products in the United States, the Middle East and Canada focused on serving...

PHILADELPHIA, Jan. 29, 2025 (GLOBE NEWSWIRE) — Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune diseases, today announced that the Company will participate in a fireside chat at Guggenheim’s SMID Cap Biotech Conference on Wednesday, February 5, 2025, at 10:30 a.m. ET in New York, NY. A live webcast of the presentation will be available on the News and Events section of the Company’s website at www.cabalettabio.com. Replays will be available on the website for 30 days. About Cabaletta BioCabaletta Bio (Nasdaq: CABA) is a clinical-stage biotechnology company focused on developing and launching the first curative targeted cell therapies designed specifically for patients with autoimmune...

Shenzhen, China, Jan. 29, 2025 (GLOBE NEWSWIRE) — ZJK Industrial Co. Ltd. (NASDAQ: ZJK) (“ZJK Industrial” or the “Company”), a high-tech precision parts and hardware manufacturer for artificial intelligence (AI) infrastructure and smart technologies, today announced that on January 11, 2025, it held a grand year-end celebration party on behalf of ZJK Industrial Group (“Group” or “ZJK Group”). Employees from all the Group’s subsidiaries—Shenzhen Zhongjinke Hardware Products Co., Ltd., Zhongke Precision Components (Guangdong) Co., Ltd., PSM-ZJK Fasteners (Shenzhen) Co., Ltd., and ZJK Vietnam Precision Components Company Limited—joined the event alongside distinguished guests, including shareholders, directors, and representatives from investors, auditing firms, law firms, and major banks. The celebration, held under the theme of...

BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) — CervoMed Inc. (NASDAQ: CRVO), a clinical stage company focused on developing treatments for age-related neurologic disorders, today announced that topline results from the Phase 2b RewinD-LB study will be presented at the 8th International Lewy Body Dementia Conference (ILBDC), being held in Amsterdam, on January 31, 2025. The initial topline results for the Phase 2b study of neflamapimod in dementia with Lewy bodies (DLB) were previously disclosed on December 10, 2024 and are available here. Details of the ILBDC presentation are as follow: Abstract Title: Efficacy and safety results of the RewinD-LB phase 2b clinical trial of neflamapimod in dementia with Lewy bodies (DLB)Format: Oral PresentationPresenter: John Alam, MD, CEO of CervoMed and Co-Principal Investigator of the RewinD-LB StudySession...

MONTREAL, Jan. 29, 2025 (GLOBE NEWSWIRE) — Premier Health of America Inc. (TSXV: PHA) (the “Corporation” or “Premier Health”), a leading Canadian health tech company, announces that its wholly owned subsidiary Canadian Health Care Agency Ltd (CHCA) was retained as service provider to provide travel nurse contingent labour services to the Nova Scotia Health Authority (NSHA). The agreement has a duration of 3 years, positions CHCA as a vendor of reference with NSHA, and covers Registered Nurses, Specialty Registered Nurses and Licensed Practical Nurses roles. The agreement, as most independent labor contract awards are, is for an execution on request contract which purpose is to meet recurring personnel needs, but for which the number, pace, or frequency of service requests are uncertain. “We are pleased to have the opportunity to...

SAN DIEGO, Jan. 29, 2025 (GLOBE NEWSWIRE) — Calidi Biotherapeutics Inc. (NYSE American: CLDI) (“Calidi”), a clinical-stage biotechnology company developing a new generation of targeted antitumor virotherapies, is pleased to invite investors to a webinar on February 5, 2025, at 4:15 p.m. ET. The exclusive event, hosted by RedChip Companies, will feature Calidi CFO Andrew Jackson and CSO Antonio F. Santidrian, PharmD. PhD, who will share insight into the company’s groundbreaking cell-based delivery platforms designed to protect, amplify, and potentiate oncolytic viruses for enhanced cancer treatment. Highlights will include overviews of Calidi’s lead programs, such as its CLD-400 systemic platform targeting metastatic cancers, CLD-201 for advanced solid tumors and CLD-101 for high-grade glioma. A live Q&A session with the leadership...

SAN FRANCISCO and BOSTON, Jan. 29, 2025 (GLOBE NEWSWIRE) — Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Guggenheim SMID Cap Biotech Conference on Wednesday, February 5, 2025 at 1:00 p.m. E.T. A live and archived webcast of the fireside chat will be available via the News & Events page in the Investors section of the Apogee Therapeutics website. About Apogee Apogee Therapeutics is a clinical-stage biotechnology company advancing novel biologics with potential for differentiated efficacy and dosing in the largest I&I markets, including for the treatment of AD, asthma, COPD, EoE and other I&I indications. Apogee’s antibody programs are designed to overcome limitations of existing therapies by targeting well-established mechanisms of...

Three Consecutive Years Without Lost-time Accidents VANCOUVER, British Columbia, Jan. 29, 2025 (GLOBE NEWSWIRE) — Amerigo Resources Ltd. (TSX: ARG; OTCQX: ARREF) (“Amerigo” or the “Company”) is pleased to announce that Minera Valle Central (“MVC”), the Company’s 100% owned operation located near Rancagua, Chile, has reached a significant safety milestone, marked by three consecutive years without lost-time accidents. During these three years, a total of 1,823,782 man-hours were lodged by MVC’s employees. “This new safety record reached by the MVC team is significant as it demonstrates the safety mindset and the effectiveness of the safety practices, training programs and tools in place at our operation. Our maxims that safety supersedes all production goals and that all workers should return home unharmed each day have clearly...